News
May 26, 2022

Icosagen gave useful tips and rewards to students

Icosagen, in collaboration with the Bioscience Students' Association, encouraged students to do scientific research, by giving them practical tips and financial rewards for their great work.
Read more ›

April 19, 2022

Diagnostic antibodies against IL-6 with high sensitivity and wide dynamic range!

Icosagen has developed high sensitivity monoclonal antibodies against IL-6 with wide dynamic range. We have 6 different antibody clones available, which experimentally show no cross-reactivity with IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-8, IFNγ, TNFα cytokines.In addition to antibodies, recombinant human IL-6 antigen is in stock.
Read more ›

March 17, 2022

Icosagen stands with Ukraine

Democracy, peace and freedom are the most fundamental values of society. Unfortunately, the unjustifiable war in Ukraine is a painful reminder that we cannot take it for granted.  Icosagen stands with Ukraine.
Read more ›

February 23, 2022

High quality Omicron antibodies and proteins now available!

Omicron variant accounts for almost all new COVID-19 cases around the world. In Icosagen we have tested our developed antibodies against different SARS-CoV-2 Spike variants, and now also with the dominant Omicron variant. We offer antibodies with high affinity to Omicron variant and also antibodies binding to other variants, without binding to Omicron.  
Read more ›

February 01, 2022

Icosagen Strengthens BD Team with Oliver Schub for Next Level Growth Stage: Stable CHO Cell Line Development and Therapeutic Protein Production

Icosagen Group has been steadily and strongly growing over the past years to more than 120 employees. We have built a world-wide reputation for therapeutic antibody discovery and recombinant antibody/protein production for our IVD, biotech, and pharma partners, based on our patented HybriFree and QMCF Technology Platforms. Recently, we successfully ventured even into the medical products world, with our Bioblock® anti-Covid19 nasal spray. 
Read more ›

January 25, 2022

SARS-CoV-2 Trimeric Spike, S1 and RBD Omicron proteins are now available!

We are keeping up with the virus by producing SARS-CoV-2 Omicron variant (B.1.1.529) as Trimeric Spike, S1 and RBD. All of these are produced recombinantly in CHO cells and shown to be functional. Furthermore, we will have Omicron version of Nucleocapsid protein available with P13L, del31-33, R203K and G204R mutations in few weeks.  
Read more ›

December 22, 2021

Seasons’s Greetings from the Icosagen Team

December 16, 2021

Omicron variant soon available!

November 11, 2021

ISR Vaccine AB signs collaboration agreement with Icosagen for vaccine pipeline

August 06, 2021

New laboratory studies suggest that BioBlock® nasal spray provides protection against all major variants of coronaviruses

May 07, 2021

Icosagen's SARS-CoV-2 Neutralizing Antibody ELISA Kit Is Available for Evaluating Immune Responses to COVID-19 and Carries an IVD CE Mark

May 04, 2021

BioBlock®, a Novel Prophylactic Nasal Spray With Antibodies Against SARS-CoV-2 Developed by Icosagen, Has Received Marketing Authorization and Is Available for Sale in Estonia

December 24, 2020

Happy holidays

October 21, 2020

Estonian Biotech Icosagen Has Developed Highly Potent Next-Generation Therapeutic and Preventative Anti-SARS-CoV-2 Neutralizing Antibodies as Promising Drug Candidates for Covid-19

October 12, 2020

KTH protein production with QMCF

September 14, 2020

Icosagen's COVID-19 antibody ELISA test is available for diagnostics with an IVD CE mark 

August 31, 2020

Carlova Consult supports Icosagen’s research and development against COVID-19

March 18, 2020

Icosagen continues to support your research

January 15, 2020

Meet us at PepTalk

December 17, 2019

Season’s Greetings!

December 05, 2019

Meet us at Antibody Engineering & Therapeutics or BioFit partnering events

June 03, 2019

Press release: Icosagen and AbCheck Announce Five-year Licensing Agreement Granting AbCheck Access to Icosagen’s Patented Mammalian Expression Technology

December 18, 2018

Meet us at PepTalk on 14th-18th of January in San Diego

December 12, 2018

Seasons Greetings!

November 06, 2018

Meet us in November at conventions and expos

October 16, 2018

Meet us at European Antibody Congress 2018 in Basel

September 18, 2018

Meet us at BIO Japan 2018

June 28, 2018

Meet Us at 70th AACC Annual Scientific Meeting in Chicago

May 30, 2018

Meet us at BIO International convention in Boston

December 18, 2017

Seasons Greetings!

October 10, 2017

Meet us at Bio Japan

July 31, 2017

Meet us at AACC 2017 in San Diego

April 18, 2017

Meet Icosagen at PEGS Boston May 1-5

February 09, 2017

Icosagen identified several high-risk HPV inhibitors and drug targets with a novel high-throughput screening assay

December 29, 2016

Meet us at PEPTalk 2017

December 19, 2016

Merry christmas!

May 05, 2016

Icosagen AS donates to SA University of Tartu Clinic's Children foundation

April 01, 2016

Icosagen developed anti-human BNDF antibody clone 3C11 played prominent role in Neuroscience and JBC publications.

April 01, 2016

HORIZON 2020 project: PROFILE Innovative Training Network

February 29, 2016

Press release: Icosagen Cell Factory was awarded EUR 1.2 million

January 11, 2016

HybriFree recombinant antibody development article is published

December 18, 2015

Seasons Greetings

September 17, 2015

Icosagen AS has incorporated a US subsidiary – Icosagen Technologies, Inc.

September 04, 2015

Icosagen Cell Factory is participating in 29th NIH Research Festival, September 16-18, 2015 in Bethesda, USA

September 04, 2015

Icosagen Cell Factory is participating first MANF and CDNF Proteins Symposium, September 14-15, San Francisco, California

June 10, 2015

Icosagen Cell Factory is participating in AACC Meeting, July 26–30, Georgia World Congress Center, Atlanta, Georgia

June 10, 2015

Icosagen Cell Factory is participating in the BIO International Convention, June 15-18, 2015, Philadelphia

December 30, 2014

The Icosagen Cell Factory OÜ team is looking for a MARKETING SPECIALIST

December 22, 2014

QMCF Technology to be presented at the CHI's 14th Annual PepTalk conference in San Diego, California

December 19, 2014

Happy Holidays from Icosagen!

October 15, 2014

Icosagen and FIT Biotech Oy begin cooperation to develop anti-ebola vaccines and biological therapeutics

October 02, 2014

Icosagen Cell Factory was titled the Best Entrepreneur of 2013

September 08, 2014

Icosagen's opening ceremony

June 10, 2014

QMCF Technology based CHO/Furin expression cell line is available

May 02, 2014

Icosagen Cell Factory attends to PEGS 2014 in Boston

February 05, 2014

Icosagen Cell Factory presentation at Cell Line Development Conference

February 03, 2014

New premises of Icosagen Group